Phase 2 Head and Neck Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with head and neck cancer that requires palliative radiotherapy (radiation treatment aimed at relieving symptoms rather than curing the disease)
• People with head and neck squamous cell cancer that cannot be surgically removed, has come back, or has spread to other parts of the body — whether or not they have previously been treated with platinum-based chemotherapy, or are currently receiving a drug called pembrolizumab as a first treatment
• People who are either already receiving a type of immunotherapy drug (pembrolizumab or nivolumab) as part of their standard care, or whose treating doctor considers them suitable to receive one of these drugs
• People who have at least one tumour that doctors can physically access to inject the study drug (RiMO-301) and treat with radiation using the methods specified in this trial
• People whose target tumour(s) can be measured on imaging scans, and where repeat measurements at the same location are possible
• People whose target tumour is not in an area that has previously been irradiated, or was irradiated at least six months before the study drug injection and caused no lasting complications
• People where the total volume of tumours being treated does not exceed 250 cm³ (up to five lesions may be treated in one patient)
• People who have recovered from the side effects of previous cancer treatments before joining the trial (side effects must be at a mild level or resolved)
• People who have adequate bone marrow function and adequate liver function
• People with a life expectancy of at least 12 weeks
• People with a general health score (ECOG scale) of 0, 1, or 2 — meaning they are able to carry out at least some daily activities independently
• People aged 18 years or older

Who may not be able to join:

• People who show signs of major organ failure, serious long-term illnesses unrelated to cancer, or other severe health conditions
• People who have cancer that has spread to the brain and is causing symptoms, or cancer affecting the membranes surrounding the brain and spinal cord
• People who have an active autoimmune disease that has needed systemic (whole-body) medical treatment within the past two years
• People who have an active, clinically significant infection at or near the tumour site being treated
• People who have had major surgery near the treatment area within 21 days before starting the study drug, or a minor surgical procedure within 7 days (note: placement of a port, feeding tube, or catheter does not require a waiting period)
• People who have received any other approved or experimental cancer treatment or immunotherapy — other than pembrolizumab or nivolumab — within four weeks before the study drug injection
• People whose tumours are located very close to, or wrapped around, major blood vessels (such as the carotid artery) or other important structures

Important: Always verify eligibility with the trial site directly before applying.